Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Patients Hospitalized with COVID-19
This item is under embargo and is only visible to journalists
Please login here
Regions: North America, United States, Canada, Latin America, Argentina, Brazil, Mexico, Asia, India
Keywords: Health, Medical
The item has been withdrawn. If you are a journalists please contact the person that posted the item with any questions.